Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons
- Sini, Valentina
- Cassano, Alessandra
- Corsi, Domenico
- DE LAURENTIIS, Michelino
- Gamucci, Teresa
- Mauri, Mariella
- Naso, Giuseppe
- Roselli, Mario
- Ruggeri, Enzo Maria
- Tonini, Giuseppe
- Vici, Patrizia
- Zampa, Germano
- Marchetti, Paolo
Publication date
January 2016
DOI Publisher
SAGE Publications ISSN
0300-8916 Citation count (estimate)
1Abstract
Bevacizumab, a humanized, anti-vascular endothelial growth factor-A monoclonal antibody, has shown efficacy in a number of cancers. However, its use in metastatic breast cancer (MBC) remains controversial
Add to ORKG